Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cytokinetics

40.52
+0.27000.67%
Post-market: 40.30-0.2200-0.54%19:23 EDT
Volume:2.74M
Turnover:112.15M
Market Cap:4.80B
PE:-7.70
High:42.37
Open:39.43
Low:39.11
Close:40.25
Loading ...

Bayer Acquires Rights for Cardiovascular Drug From CYTK in Japan

Zacks
·
20 Nov 2024

Cytokinetics Price Target Maintained With a $72.00/Share by Needham

Dow Jones
·
20 Nov 2024

Cytokinetics Gains ‘Buy’ Rating Due to Strategic Collaborations and Potential FDA Approval

TIPRANKS
·
20 Nov 2024

Cytokinetics partnership demonstrates value of aficamten, says JMP Securities

TIPRANKS
·
20 Nov 2024

Cytokinetics Secures Strategic Licensing Deal with Bayer, Boosting Global Prospects for Aficamten

TIPRANKS
·
20 Nov 2024

Cytokinetics, Bayer in Japan Licensing Pact for Aficamten

Dow Jones
·
19 Nov 2024

Cytokinetics, Bayer enter collaboration and license pact for aficamten in Japan

TIPRANKS
·
19 Nov 2024

Deals of the day-Mergers and acquisitions

Reuters
·
19 Nov 2024

Cytokinetics, Bayer Partner to Develop, Commercialize Potential Cardiomyopathy Treatment in Japan

MT Newswires Live
·
19 Nov 2024

Cytokinetics Will Get More Revenue for Marketing Aficamten in Japan

GuruFocus.com
·
19 Nov 2024

Bayer acquires rights to Cytokinetics' heart drug in Japan

Reuters
·
19 Nov 2024

BRIEF-Bayer Strengthens Cardiovascular Portfolio With Cytokinetics' Aficamten In Japan

Reuters
·
19 Nov 2024

BRIEF-Cytokinetics And Bayer Announce Exclusive Licensing Collaboration For Aficamten In Japan

Reuters
·
19 Nov 2024

Cytokinetics Inc - Bayer to Conduct Phase 3 Trial in Japanese Patients With Obstructive HCM

THOMSON REUTERS
·
19 Nov 2024

Cytokinetics and Bayer Announce Exclusive Licensing Collaboration for Aficamten in Japan

THOMSON REUTERS
·
19 Nov 2024

Cytokinetics Inc - Eligible for up to €490 Million in Commercial Milestones

THOMSON REUTERS
·
19 Nov 2024

Cytokinetics Price Target Maintained With a $120.00/Share by HC Wainwright & Co.

Dow Jones
·
18 Nov 2024

Positive Clinical Outcomes Drive Buy Rating for Cytokinetics’s Cardiac Myosin Modulators

TIPRANKS
·
18 Nov 2024

Cytokinetics Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy at the American Heart Association Scientific Sessions 2024

THOMSON REUTERS
·
16 Nov 2024

Cytokinetics Price Target Maintained With a $120.00/Share by HC Wainwright & Co.

Dow Jones
·
12 Nov 2024